Skip to main content

Advertisement

SpringerLink
Log in

Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The present study was conducted to investigate Epstein-Barr virus (EBV) reactivation after hematopoietic cell transplantation (HCT) in Korean children living in an area of a high seroprevalence against EBV and to determine the impact of recipient age on EBV reactivation. Medical records of 248 children and adolescents who had received allogeneic HCT were retrospectively reviewed. The trends of EBV reactivation and post-transplant lymphoproliferative disorders (PTLDs) were evaluated and compared between younger (≤10 years old) and older (11–20 years old) groups. EBV reactivation occurred in 177 cases (71.4 %) and high-level EBV reactivation, defined as a virus DNA titer of 300,000 copies/mL or higher, occurred in 21 cases (8.5 %). PTLD was diagnosed in five cases (2.0 %), and one of these patients died. The EBV reactivation rate was not significantly different between the two age groups; however, high-level reactivation and PTLD were more significantly frequent in the older than in the younger group (P = 0.030 and P = 0.026, respectively). In conclusion, older children and adolescents are more likely to experience high-level EBV reactivation and PTLDs, and higher EBV DNA titers than those previously reported may be a predictor of PTLD in areas with a high seroprevalence against EBV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Odumade OA, Hogquist KA, Balfour HH Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24:193–209.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis. 2001;3:79–87.

    Article  CAS  PubMed  Google Scholar 

  3. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol. 2005;49:285–92.

    CAS  PubMed  Google Scholar 

  4. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev. 2010;23:350–66.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Heslop HE. How I treat EBV lymphoproliferation. Blood. 2009;114:4002–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Omar H, Hagglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis. 2009;11:393–9.

    Article  CAS  PubMed  Google Scholar 

  7. Park SH, Choi SM, Lee DG, Choi JH, Yoo JH, Kim HJ, et al. Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea. J Korean Med Sci. 2006;21:259–64.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Sundin M, Le Blanc K, Ringden O, Barkholt L, Omazic B, Lergin C, et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059–67.

    PubMed  Google Scholar 

  9. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008;42:181–6.

    Article  CAS  PubMed  Google Scholar 

  10. Oh SH, Lee YA, Moon WY, Ko TS, Park YS, Moon HN, et al. Prevalence of Epstein-Barr virus (EBV) antibody in Korean children. J Korean Pediatr Soc. 1994;37:804–11.

    Google Scholar 

  11. Takeuchi K, Tanaka-Taya K, Kazuyama Y, Ito YM, Hashimoto S, Fukayama M, et al. Prevalence of Epstein-Barr virus in Japan: trends and future prediction. Pathol Int. 2006;56:112–6.

    Article  PubMed  Google Scholar 

  12. Hoshino Y, Kimura H, Tanaka N, Tsuge I, Kudo K, Horibe K, et al. Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation. Br J Haematol. 2001;115:105–11.

    Article  CAS  PubMed  Google Scholar 

  13. Chen DB, Song QJ, Chen YX, Chen YH, Shen DH. Clinicopathologic spectrum and EBV status of post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2013;97:117–24.

    Article  CAS  PubMed  Google Scholar 

  14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1994;15:825–8.

    Google Scholar 

  15. Styczynski J, Reusser P, Einsele H, de la Camara R, Cordonnier C, Ward KN, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant. 2009;43:757–70.

    Article  CAS  PubMed  Google Scholar 

  16. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood. 1999;94:3294–306.

    CAS  PubMed  Google Scholar 

  17. van Esser JW, Niesters HG, van der Holt B, Meijer E, Osterhaus AD, Gratama JW, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–9.

    Article  PubMed  Google Scholar 

  18. Clave E, Agbalika F, Bajzik V, de Latour Peffault R, Trillard M, Rabian C, et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation. 2004;77:76–84.

    Article  CAS  PubMed  Google Scholar 

  19. Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011;155:377–85.

    Article  CAS  PubMed  Google Scholar 

  20. van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98:972–8.

    Article  PubMed  Google Scholar 

  21. Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, et al. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention? Pediatr Blood Cancer. 2006;47:200–5.

    Article  PubMed  Google Scholar 

  22. Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence, kinetics, and risk factors of Epstein-Barr virus viremia in pediatric patients after allogeneic stem cell transplantation. Pediatr Transplant. 2012;16:144–50.

    Article  CAS  PubMed  Google Scholar 

  23. Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, et al. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis. 2013;15:259–67.

    Article  CAS  PubMed  Google Scholar 

  24. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54.

    Article  CAS  PubMed  Google Scholar 

  25. Opelz G, Daniel V, Naujokat C, Döhler B. Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma. Transplantation. 2009;88:962–7.

    Article  PubMed  Google Scholar 

  26. Chan TS, Hwang YY, Gill H, Au WY, Leung AY, Tse E, et al. Post-transplant lymphoproliferative diseases in Asian solid organ transplant recipients: late onset and favorable response to treatment. Clin Transplant. 2012;26:679–83.

    Article  PubMed  Google Scholar 

  27. Kullberg-Lindh C, Mellgren K, Friman V, Fasth A, Ascher H, Nilsson S, et al. Opportunistic virus DNA levels after pediatric stem cell transplantation: serostatus matching, anti-thymocyte globulin, and total body irradiation are additive risk factors. Transpl Infect Dis. 2011;13:122–30.

    Article  CAS  PubMed  Google Scholar 

  28. Schönberger S, Meisel R, Adams O, Pufal Y, Laws HJ, Enczmann J, et al. Prospective, comprehensive, and effective viral monitoring in children undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:1428–35.

    Article  PubMed  Google Scholar 

  29. van Tol MJ, Gerritsen EJ, de Lange GG, van Leeuwen AM, Jol-van der Zijde CM, Oudeman-Gruber NJ, et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood. 1996;87:818–26.

    PubMed  Google Scholar 

  30. Yamazaki R, Nakasone H, Tanaka Y, Sato M, Terasako K, Wada H, et al. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:1013–20.

    Article  CAS  PubMed  Google Scholar 

  31. Opelz G, Daniel V, Naujokat C, Fickenscher H, Döhler B. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis. Lancet Oncol. 2007;8:212–8.

    Article  CAS  PubMed  Google Scholar 

  32. Meij P, van Esser JW, Niesters HG, van Baarle D, Miedema F, Blake N, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003;101:4290–7.

    Article  CAS  PubMed  Google Scholar 

  33. Chakrabarti S, Milligan DW, Pillay D, Mackinnon S, Holder K, Kaur N, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood. 2003;102:839–42.

    Article  CAS  PubMed  Google Scholar 

  34. Hoegh-Petersen M, Goodyear D, Geddes MN, Liu S, Ugarte-Torres A, Liu Y, et al. High incidence of post transplant lymphoproliferative disorder after antithymocyte globulin-based conditioning and ineffective prediction by day 28 EBV-specific T lymphocyte counts. Bone Marrow Transplant. 2011;46:1104–12.

    Article  CAS  PubMed  Google Scholar 

  35. Castagnola E, Cappelli B, Erba D, Rabagliati A, Lanino E, Dini G. Cytomegalovirus infection after bone marrow transplantation in children. Hum Immunol. 2004;65:412–22.

    Article  Google Scholar 

  36. Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, et al. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant. 2013;27:E491–7.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

There is no conflict of interest for all authors.

Author information

Authors and Affiliations

  1. Department of Pediatrics, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 137-701, Republic of Korea

    Seung Beom Han, E Young Bae, Jae Wook Lee, Pil Sang Jang, Nack-Gyun Chung, Dae Chul Jeong, Bin Cho, Soon Ju Lee, Jin Han Kang & Hack-Ki Kim

  2. Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Seung Beom Han, E Young Bae, Dong-Gun Lee & Jin Han Kang

  3. Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Jae Wook Lee, Dong-Gun Lee, Nack-Gyun Chung, Bin Cho & Hack-Ki Kim

  4. Division of Infectious Diseases, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

    Dong-Gun Lee

Authors
  1. Seung Beom Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Young Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae Wook Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pil Sang Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dong-Gun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nack-Gyun Chung
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dae Chul Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bin Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Soon Ju Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jin Han Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hack-Ki Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bin Cho.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Han, S.B., Bae, E.Y., Lee, J.W. et al. Features of Epstein-Barr virus reactivation after allogeneic hematopoietic cell transplantation in Korean children living in an area of high seroprevalence against Epstein-Barr virus. Int J Hematol 100, 188–199 (2014). https://doi.org/10.1007/s12185-014-1613-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-014-1613-z

Keywords

Search

Navigation